Source: International Congress 2018 – New drugs, strategies and research designs for advanced non-small cell lung cancer



Rating:

Share or cite this content

Citations should be made in the following way:
J. Cadranel (Paris Cedex 20, France). Immunotherapy: when, who and which drug?. International Congress 2018 – New drugs, strategies and research designs for advanced non-small cell lung cancer

Member's Comments

No comment yet.

Related content which might interest you: Antiviral drugs: which and when? Source: Annual Congress 2006 - Influenza: from avian flu to pandemia? Year: 2006 Anti-tuberculosis drugs : what is new? / Nouveaux médicaments antituberculeux: quoi de neuf ? Source: International Congress 2018 – French Programme 2018: Part II Year: 2018 Evaluating disease-modifying treatment in CF: are we ready to take the challenge? Source: International Congress 2014 – Ceremony for the ERS Rare Pulmonary Disease Research Award 2014 followed by the symposium "Challenges in endpoints for rare lung diseases" Year: 2014 Antituberculosis fixed multi-dose combination and single drug therapy in active tuberculosis: What is about drug hypersensitivity reactions? Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma Year: 2016 Immunotherapy in SCLC: small step or leap? Source: Virtual Congress 2020 – Exciting new developments in lung cancer screening, diagnostics and treatment Year: 2020 Immunotherapy (as an adjuvant therapeutic tool) of tuberculosis - does it have a future? Source: Annual Congress 2005 - Challenges in the management of pulmonary tuberculosis: a continuous clinical problem Year: 2005 Optimising bronchodilator therapy in COPD: Who, why and when? Source: International Congress 2019 – Personalised medicine in COPD: Matching the patient needs with the right care Year: 2019 Long-term oral antibiotic treatment: why, what, when and to whom? Source: Eur Respir Monogr 2017; 75: 185-205 Year: 2017 Positional therapy: who, when and how? Source: Sleep and Breathing Conference 2021 Year: 2021 Making clinical sense of the explosion in biologics - which drug for which patient and why? Source: International Congress 2019 – PG10 Severe asthma in adults: systematic assessment and biological treatment Year: 2019 Fixed-dose combination and therapeutic drug monitoring in tuberculosis: friend or foe? Source: Eur Respir J 2016; 48: 1230-1233 Year: 2016 TB vaccination: why, when, how and what? Source: International Congress 2014 – PG20 Global evaluation of tuberculosis from children to adults Year: 2014 Treatment for NTM: when, how... and what next? Source: ERS Course 2015 Year: 2015 TB following targeted and biological therapy: can we predict it? Source: Virtual Congress 2020 – Tuberculosis and comorbidities Year: 2020 Targeted therapies for lung cancer: how did the game begin? Source: Breathe 2016; 12: 177-179 Year: 2016 Pharmacotherapy of CSA: who, when and how? Source: Sleep and Breathing Conference 2021 Year: 2021 Asthma control test: how? And where? Source: Annual Congress 2008 - Asthma control or asthma severity Year: 2008